Yang Rui has never made a new drug completely, it is too time-consuming and unnecessary.

There are very few pharmaceutical companies in the world that will make a new drug and sell it from beginning to end, for the same reason - a 20-year payment cycle is unbearable for normal pharmaceutical companies. What is a century-old store, a two-hundred-year-old enterprise, if you spend all your time on the development of one drug after another, you can only make a few in your lifetime, and you have to guard against a six-sevenths chance of failure......

Even super pharmaceutical companies have their own focuses, such as the most famous Pfizer, their strongest ability is sales. Of course, this is not to say that their manufacturing and R&D capabilities are weak, such as sildenafil, the main ingredient in Viagra, which was developed by Pfizer's subsidiary.

Historically, it took them about six or seven years to find a suitable active compound, and then it took five or six years to verify that sildenafil has little effect on lowering blood pressure......

As for developing it into Viagra, it's not so much about luck as it is about fighting to the death!

For Pfizer, the failure to develop a new drug is an inevitable situation, and there must be a few new drugs declared to fail in any year.

But how many decades are there in the life of a researcher who is dedicated to it?

For the researcher in charge of the project, the cost of investment is even higher, he has to spend at least ten years to accumulate experience, maybe fifteen to twenty years, before he has the opportunity to preside over such a project, this is not counting the previous academic investment, and the failure of a new drug, especially the first new drug in his life, will be disastrous.

Being the head of the laboratory is like being the director of a film.

Investors allow you to fail, and you can afford to lose some in the short term, or even a small loss in the long term, just like a film with an investment of 10 million, and a box office of 10 million is not completely unacceptable. Directors who make this kind of film will not be sought after or even popular, but they can still find a job.

However, if it is an investment of $30 million in the research and development of a new drug, and the "box office" results are zero, what do investors think?

Will the researcher in charge of this project be able to find a new project?

Of course, the situation of complete loss in the development of new drugs is still relatively rare.

Especially when you zoom in on the time horizon, developing new compounds is the least risky – relative to the overall drug development process.

It is also because of this that Yang Rui started with compounds at the beginning.

It has the lowest requirements for laboratories, the least requirements for researchers, and most importantly, as long as the cost is controlled, no matter how bad the compound is, it can be sold for money.

In other words, there are no rotten compounds, only medical experts who can't find a use. For example, the first to be found by the Japanese Endo Akira was the first to find mevastatine. The Sankyo Pharmaceutical team led by Akira Endo spent more than two years screening more than 6,000 different microorganisms to find the compound, and then spent another seven years to complete clinical trials.

However, around 80 years ago, the Japanese stopped clinical trials, and the proportion of malignant tumors in dogs that were tested on animals increased alarmingly.

In 78 years, Merck Sharp & Dohme, which screened out similar compounds, originally wanted to pick up a cheap one, but did not expect that this situation would occur when the compound that had just spent a huge amount of money to make, in order not to let the previous investment go to waste, so it had to continue the clinical trial with anxiety, and finally succeeded in luck, opening the sales of the 10-billion-level blockbuster lovastatin.

Therefore, although the opportunity of compound pit people is great, they can still sell for money after all.

Buying and selling chemical compounds is also a very common thing in the pharmaceutical world.

The deferiprone compound made by Yang Rui has reached the milestone of selling and has now gained hundreds of millions of dollars. Although the new drug for Gaucher disease was handed over to Northern Pharmaceutical, it was also Yang Rui's good start, so that foreign companies such as Jielikang were willing to take the money to participate.

The compound of sildenafil, before 92 years, was neither expensive nor cheap.

Pfizer still has expectations for it: a blood pressure-lowering drug, if it works well, it is a proper bombshell. If you sell $1 billion a year, you have to make at least a few hundred million dollars in profits.

It is also for this expectation that Pfizer can endure tens of millions of dollars a year.

However, by the time sildenafil was proven clinically ineffective around 92, its value plummeted.

However, Yang Rui is not qualified to go to the card time.

Even if it is a useless compound, it will become more expensive in the hands of Pfizer, which is well known in the market.

If they dragged it around and let them discover something strange, Yang Rui would not be able to cut it off.

Therefore, Yang Rui made a decision and sent two employees from Sinovel to contact Pfizer.

At the same time, Yang Rui also let out the wind, saying that Sinovel is ready to further develop pharmaceutical research and development capabilities......

Comrade Li Zhangzhen of Sinovel Company is very happy about this.

As the person in charge of the company, the larger the company and the more projects there are, the stronger the sense of accomplishment.

Compared with simply doing pharmaceutical sales, the integration of production, education and research sounds much more handsome.

Comrade Li Zhangzhen's happiness lasted for about a week.

In the blink of an eye, his excitement disappeared from his eyes, and when he met Yang Rui, his face was even more frustrated: "Pfizer refused." ”

"Oh, what reason?" Yang Rui was not surprised.

"There's no good reason why they don't want to sell sildenafil right now. Li Zhangzhen's words were full of regret, and then asked: "Do you have any other goals?"

"Pfizer refused so directly?" Yang Rui was more concerned about Li Zhangzhen's attitude, he obviously gave up completely.

Li Zhangzhen nodded helplessly, and said: "Pfizer said that since it is a compound that Nobel Prize winner Mr. Yang Rui is optimistic about, they will at least increase their investment to give it a try." ”

"Uh......" Yang Rui thought of such a possibility, but it was still a little embarrassing to be said directly.

"The main thing is that the safety test of sildenafil is very good, and Pfizer still has some illusions about it. Li Zhangzhen sighed.

Yang Rui said disapprehantly: "Antihypertensive drugs are commonly used medicines, and patients have to take them every day. There is a lot of competition in the market, and the security is not good, so there is no value for development at all. ”

"But it's not easy to find safe compounds. Li Zhangzhen said regretfully: "Pfizer didn't mention the price, so I should be completely uninterested." ”

"En......" Yang Rui groaned slightly.

"Actually, I learned that there are many good antihypertensive compounds on the market, and it may be easier to buy them from small companies......

"Since it's not a matter of price, let's look for a breakthrough from another angle. Yang Rui didn't answer Li Zhangzhen's stubble at all, and said to himself: "You ask them to consult Pfizer, just say it...... Let's change the market for technology. ”

"Market, what market?" Li Zhangzhen still didn't wake up.

"Of course, it is the Chinese market. Yang Rui said with the posture of a GMP committee boss: "You just tell them like this, if they don't want to talk to us, if Pfizer's new drug wants to enter the Chinese market in the future, there is no need to talk about it." ”

There should be BGM here!

……

nt

Remember the mobile version URL: m.